ZyVersa Therapeutics (ZVSA) Projected to Post Quarterly Earnings on Monday

ZyVersa Therapeutics (NASDAQ:ZVSA) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect ZyVersa Therapeutics to post earnings of ($0.30) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, April 2, 2026 at 9:30 AM ET.

ZyVersa Therapeutics Price Performance

Shares of NASDAQ:ZVSA opened at $0.19 on Friday. The stock has a market cap of $1.54 million, a price-to-earnings ratio of -0.14 and a beta of 0.66. The company has a 50 day moving average of $0.22 and a 200-day moving average of $0.17. ZyVersa Therapeutics has a one year low of $0.11 and a one year high of $1.94.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.